Literature DB >> 18454784

Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria.

Rohit Bhatia, Deepti Vibha, M V Padma Srivastava, Kameshwar Prasad, Manjari Tripathi, Mamta Bhushan Singh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454784     DOI: 10.1111/j.1528-1167.2007.01518_2.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


× No keyword cloud information.
  6 in total

1.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

2.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Porphyria: An Uncommon Cause of Posterior Reversible Encephalopathy Syndrome.

Authors:  Vinay Agarwal; Namit Singhal
Journal:  J Pediatr Neurosci       Date:  2019-09-27

Review 4.  Acute porphyrias - A neurological perspective.

Authors:  Lea M Gerischer; Franziska Scheibe; Astrid Nümann; Martin Köhnlein; Ulrich Stölzel; Andreas Meisel
Journal:  Brain Behav       Date:  2021-10-17       Impact factor: 2.708

5.  Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome and lateralized periodic discharges plus fast activity on EEG.

Authors:  Diosely C Silveira; Mahrukh Bashir; Joshua Daniel; Michelle H Lucena; Frank Bonpietro
Journal:  Epilepsy Behav Case Rep       Date:  2016-08-25

6.  Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India.

Authors:  Susheel Kumar; Ashish Bhalla; Navneet Sharma; Deba Prasad Dhibar; Savita Kumari; Subhash Varma
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.